PMID- 28064419
OWN - NLM
STAT- MEDLINE
DCOM- 20180712
LR  - 20211204
IS  - 2107-0180 (Electronic)
IS  - 0378-7966 (Linking)
VI  - 42
IP  - 5
DP  - 2017 Oct
TI  - Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.
PG  - 729-744
LID - 10.1007/s13318-016-0397-3 [doi]
AB  - Although carbamazepine is one of the oldest anticonvulsant drugs, it is still 
      heavily utilized for treatment of epilepsy in children. The aim of this article 
      was to review the current knowledge about pharmacokinetics and pharmacogenetics 
      of carbamazepine in children. The literature for this review was systematically 
      searched for in the MEDLINE and SCINDEKS databases. Oral bioavailability of 
      carbamazepine in children is about 75-85%, and it is approximately 75-85% bound 
      to plasma proteins. Apparent volume of distribution is 1.2-1.9 l/kg and total 
      clearance between 0.05 and 0.1 l/h/kg. Pharmacokinetics of carbamazepine in 
      children is age and body weight dependent and highly variable due to influence of 
      dosing regimen and co-medication. The current evidence on the importance of 
      pharmacogenetics for carbamazepine efficacy and safety in children supports the 
      association of PXR*1B, HNF4a rs2071197, CYP1A2*1F, ABCC2 1249G>A, and PRRT2 
      c.649dupC with either pharmacokinetics or pharmacodynamics of carbamazepine. The 
      importance of human leukocyte antigen (HLA) typing for prediction of adverse drug 
      reactions to carbamazepine in children is also confirmed. Both genetic and 
      environmental factors are responsible for shaping pharmacokinetics and 
      pharmacodynamics of carbamazepine in children. To ensure safe and effective use 
      of carbamazepine in this population, physicians should adjust dosing regimen 
      according to existing pattern of genetic and environmental influences.
FAU - Djordjevic, Natasa
AU  - Djordjevic N
AD  - Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 
      Street, 69, 34000, Kragujevac, Serbia.
FAU - Jankovic, Slobodan M
AU  - Jankovic SM
AD  - Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 
      Street, 69, 34000, Kragujevac, Serbia. slobnera@gmail.com.
FAU - Milovanovic, Jasmina R
AU  - Milovanovic JR
AD  - Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 
      Street, 69, 34000, Kragujevac, Serbia.
LA  - eng
GR  - 175007/Ministarstvo Prosvete, Nauke i Tehnoloskog Razvoja/
PT  - Journal Article
PT  - Review
PL  - France
TA  - Eur J Drug Metab Pharmacokinet
JT  - European journal of drug metabolism and pharmacokinetics
JID - 7608491
RN  - 0 (ABCC2 protein, human)
RN  - 0 (Anticonvulsants)
RN  - 0 (Multidrug Resistance-Associated Protein 2)
RN  - 33CM23913M (Carbamazepine)
SB  - IM
MH  - Anticonvulsants/*pharmacokinetics/*pharmacology
MH  - Carbamazepine/*pharmacokinetics/*pharmacology
MH  - Child
MH  - Epilepsy/*drug therapy/genetics
MH  - Humans
MH  - Multidrug Resistance-Associated Protein 2
MH  - Pharmacogenetics/methods
OTO - NOTNLM
OT  - Carbamazepine
OT  - Conventional Tablet
OT  - Epileptic Child
OT  - Human Leukocyte Antigen
OT  - Stiripentol
EDAT- 2017/01/09 06:00
MHDA- 2018/07/13 06:00
CRDT- 2017/01/09 06:00
PHST- 2017/01/09 06:00 [pubmed]
PHST- 2018/07/13 06:00 [medline]
PHST- 2017/01/09 06:00 [entrez]
AID - 10.1007/s13318-016-0397-3 [pii]
AID - 10.1007/s13318-016-0397-3 [doi]
PST - ppublish
SO  - Eur J Drug Metab Pharmacokinet. 2017 Oct;42(5):729-744. doi: 
      10.1007/s13318-016-0397-3.